Li, Mao <br/><br/>
Preclinical pharmacology of the novel antitumor agent adaphostin, a tyrphostin analog that inhibits bcr/abl.  [electronic resource] 

 -  Cancer chemotherapy and pharmacology  May 2006 
 - 607-14 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0344-5704 
<br/><br/><label>Standard No.: </label>10.1007/s00280-005-0094-4  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adamantane--analogs & derivatives<br/>Animals<br/>Antineoplastic Agents--pharmacokinetics<br/>Blood Proteins--metabolism<br/>Chromatography, High Pressure Liquid<br/>Dogs<br/>Drug Evaluation, Preclinical<br/>Drug Stability<br/>Humans<br/>Hydroquinones--pharmacokinetics<br/>Injections, Intraperitoneal<br/>Injections, Intravenous<br/>Metabolic Clearance Rate<br/>Mice<br/>Proto-Oncogene Proteins c-abl--antagonists & inhibitors<br/>Proto-Oncogene Proteins c-bcr--antagonists & inhibitors<br/>Rats<br/>Rats, Inbred F344